Becton, Dickinson and Company
Thomas E Polen Jr (Chairman, CEO and President) sells BDX shares
AI-generated summary
Thomas E Polen Jr, Chairman, CEO and President, Director of Becton, Dickinson and Company, exercised 20,239 shares for $3.6M, sold 17,246 shares back to the company for $3.6M, and sold 2,993 shares for $628.5K. Following these transactions, the insider directly held 110,163 shares. The transactions were made under a Rule 10b5-1 trading plan adopted on March 2, 2026.
Key facts
- Insider
- Thomas E Polen Jr · Chairman, CEO and President, Director
Rule 10b5-1 plan · adopted Mar 2, 2026
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | M · exercise or conversion of a derivative | +20,239 | $178.94 | $3,621,566.66 | 130,402 | Direct |
| Nov 5, 2026 | D · sale back to the company | −17,246 | $210.00 | $3,621,660.00 | 113,156 | Direct |
| Nov 5, 2026 | S · open-market sale | −2,993 | $210.00 | $628,530.00 | 110,163 | Direct |
| Nov 5, 2026 | M · exercise or conversion of a derivativeStock Appreciation RightsFootnotes F1, F2 | −20,239 | $0.00 | $0.00 | 20,239 | Direct |
Footnotes
- F1 Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
- F2 The stock appreciation rights vest in four annual installments beginning November 26, 2019.
Remarks: The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026.
More BDX filings
- 144
Filed Nov 5, 2026
- 8-K
Filed Nov 5, 2026
- 4
Filed Oct 27, 2026
- 144
Filed Oct 26, 2026
- 4
Filed Sep 29, 2026
- 144
Filed Sep 28, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.